A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor has anti-tumour effects in estrogen receptor positive breast cancer patients.
University of Louisville scientists aim to disarm Yersinia pestis, the bubonic plague bacteria
When the body encounters bacteria, viruses or harmful substances, its innate immune cells, neutrophils, assemble at the site to combat the invader.
January 6, 2024